Regeneron-licensed obesity drug shows positive phase 3 results in China
Source: SeekingAlpha
2026-03-09 08:06:09 ET
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Why Dupixent Keeps Regeneron A Top Big Pharma Pick
- Regeneron: Expect Double-Digit Growth In 2026
- FDA plans to relax testing rules to encourage biosimilar drugs: report
- EMA panel recommends Dupixent indication for urticaria in children
Read the full article on Seeking Alpha
For further details see:
Regeneron-licensed obesity drug shows positive phase 3 results in China
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-1.59% G/L:
$742.885 Last:
150,713 Volume:
$754.55 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
